Sandy Cove Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sandy Cove Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-604	Closed	-$54K	–	392
2022 Q1	$54K	Hold	604	–	–	0.04%	190
2021 Q4	$68K	Buy	+604	New	+$72.8K	0.06%	160

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Sandy Cove Advisors's XBI Position: Q2 2022 in Review

Sandy Cove Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 604 shares — an estimated $54K sold.

Sandy Cove Advisors first reported a position in XBI in Q4 2021 and held it in 2 quarters. The position peaked at $68K in Q4 2021. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Sandy Cove Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
Sandy Cove Advisors sold 604 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $54K.
Sandy Cove Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 2 quarters.
Sandy Cove Advisors's State Street SPDR S&P Biotech ETF position peaked at $68K in Q4 2021.
706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Sandy Cove Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.